SanBio Co (TSE:4592) Tax Expense: 円-172.61 Mil (TTM As of Jan. 2026)


TSE:4592 SanBio Co Ltd TSE:4592
22 GF Score
Price 円989.00
! 1 Warning Sign
View Full Analysis

What is SanBio Co Tax Expense?

SanBio Co TSE:4592 -0.80% 22 Tax Expense is 円-172.61 Mil as of Jan. 2026. GuruFocus rates TSE:4592 with a GF Score™ of 22/100. The stock has 1 warning sign investors should review.

SanBio Co's tax expense for the months ended in Jan. 2026 was 円-3.47 Mil. Its tax expense for the trailing twelve months (TTM) ended in Jan. 2026 was 円-172.61 Mil.


SanBio Co  (TSE:4592) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


SanBio Co Tax Expense Related Terms


SanBio Co Tax Expense Historical Data

* Premium members only.

The historical data trend for SanBio Co's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SanBio Co Tax Expense Chart

SanBio Co Annual Data
Trend Jan17 Jan18 Jan19 Jan20 Jan21 Jan22 Jan23 Jan24 Jan25 Jan26
Tax Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 117.43 862.14 102.20 -127.78 -449.13

SanBio Co Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Tax Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -218.79 -265.95 39.08 -3.47 57.73
TSE:4592
22GF Score
SanBio Co Ltd TSE:4592
Tax Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SanBio Co Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Jan. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-172.61 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Tax Expense →
What does a Tax Expense of 円-172.61 Mil mean?
SanBio Co (TSE:4592) has a Tax Expense of 円-172.61 Mil as of Jan. 2026. Tax expense is the amount of tax the company pays in an accounting period. View historical data on SanBio Co and its competitors.
Is SanBio Co's Tax Expense too high?
SanBio Co's current Tax Expense is 円-172.61 Mil. Overall, SanBio Co has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does SanBio Co's Tax Expense compare to VRTX and REGN?
SanBio Co's Tax Expense of 円-172.61 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Expense for a Biotechnology company?
A good Tax Expense depends on the Biotechnology industry context. However, Tax Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Expense mean?
A high Tax Expense can signal that a stock is expensive relative to its fundamentals. Tax expense is the amount of tax the company pays in an accounting period. View historical data on SanBio Co and its competitors. SanBio Co's current Tax Expense is 円-172.61 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SanBio Co stock overvalued right now?
SanBio Co (TSE:4592) has a current Tax Expense of 円-172.61 Mil. The current Tax Expense is 円-172.61 Mil. SanBio Co's overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Expense calculated?
Tax Expense is calculated from a company's financial statements. For SanBio Co (TSE:4592), the current Tax Expense is 円-172.61 Mil as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

SanBio Co Business Description

Address 8-1 Street Luke Tower 32nd Floor, Akashi-cho, Chuo-ku, Tokyo, JPN, 104-0044
SanBio Co Ltd is engaged in the research and development of regenerative cells drugs. The company has three types of drugs under development, including nerve regeneration cell SB623, used for the treatment of chronic cerebral infarction, traumatic brain injury, age-related macular degeneration, retinitis pigmentosa, Parkinson's disease, spinal cord injury and Alzheimer's disease; enhanced type-mesenchymal stem cells SB618, used to treat peripheral neuropathy, as well as muscle stem cells SB308, used in the treatment of muscular dystrophy.
22GF Score

Get the complete analysis for TSE:4592

Tax Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円989.00
Price